Abstract

DAPRODUSTAT: A NOVEL THERAPY FOR CKD-RELATED ANEMIA

V. Naga Divya* and Dr. M. Sri Ramachandra

ABSTRACT

Chronic kidney disease (CKD) patients often suffer fromcomplications such as anemia as the kidney function declines. Morethan 25% of CKD hemodialysis patients in China are complicated withrenal anemia due to renal and hepatic impairment in the pro duction oferythropoietin (EPO). In recent years, prolyl hydroxylase domain(PHD) inhibitors have been approved in China and Japan for thetreatment of CKD patients complicated with anemia. Currentmanagement of anemia in CKD primarily consists of an injec tableerythropoiesis stimulating agent (ESA), administered intravenously(IV) or subcutaneously (SC), and adjuvant iron therapy orally or IV.We use the term ESA to encompass short acting recombinant humanerythropoietin (rhEPO; epoetin), medium acting dar bepoetin alpha ,and long acting epoetin beta pegol. Suboptimal response to treatmentmakes pediatric CKD patients vulnerable to requiring bloodtransfusions, which may adversely affect future transplantation throughallosensitization,increase waiting tim e to transplant, and increase the risk of graft failure after transplant.

Keywords: .